The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View mds content recommended for you

As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site aml-hub.com.

EHA2022 abstracts: What's hot in MDS?

By Claire Aukim-Hastie,Becky Gribbell,Ella Dixon

Jun 6, 2022

To help navigate the exciting content being presented at the EHA2022 Congress, the MDS Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MDS.

Top abstracts

P496	Clinical characteristics of secondary myeloid neoplasms in patients with inflammatory bowel disease
P508	Real life experience using front-line CPX-351 for therapy-related and AML-MRC: Results from the Spanish PETHEMA registry
P735	The role of SF3B1 mutations in myelodysplastic syndromes
P741	DDX41 mutations define a unique subtype of myeloid neoplasms
P752	Targeting S100A9 in the myelodysplastic inflammatory bone marrow microenvironment by tasquinimod improves the supportive function of mesenchymal stromal cells
P754	Initial results of phase I/II study of azacitidine in combination with quizartinib for patients with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutation
P757	Results of a phase 1 study of azacitidine combined with venetoclax for treatment-naive and relapsed high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
P763	Venetoclax with azacitidine in relapse/refractory higher risk myelodysplastic syndrome: updated phase 1 results
P778	Long-term utilization and benefit of luspatercept in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial
P780	Combination therapy of eltrombopag and cyclosporine A can improve hematopoiesis in patients with lower risk myelodysplastic syndrome
P784	A phase I/II study of venetoclax in combination with ASTX727 (decitabine/cedazuridine) in treatment‐naïve high‐risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
P785	Current cardiovascular disease risk prediction models are not applicable in MDS patients: preliminary results of a prospective observational single-centre cohort study
PB1926	Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among US patients with lower-risk myelodysplastic syndromes (LR-MDS)
S160	Molecular determinants of disease progression after hypomethylating agent therapy in Ras pathway mutant chronic myelomonocytic leukemia at the single-cell level
S165	Integrated genetic diagnostics of patients with early onset of de novo myelodysplastic syndromes
S166	Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
S167	Prediction of relapse after allogeneic stem cell transplantation using individualized measurable residual disease markers; the prospective Nordic study NMDSG14B
S168	Erythropoietin stimulation agents significantly improves outcome in lower risk MDS
S169	Clinical and molecular markers for predicting response to romiplostim treatment in lower-risk myelodysplastic syndromes

EHA2022 abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022

Subscribe to get the best content delivered to your inbox

EHA2022 abstracts: What's hot in MDS?

Top abstracts

Newsletter

Areas of interest